Lead Product(s) : Luxdegalutamide,Abiraterone Acetate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,160.0 million
Deal Type : Licensing Agreement
Arvinas Partners with Novartis On Global License for PROTAC® ARV-766
Details : Novartis obtains worldwide development & commercialization rights to ARV-766, Arvinas’ 2nd-generation PROTAC androgen receptor degrader for prostate cancer, including its preclinical AR-V7 program.
Brand Name : ARV-766
Molecule Type : Small molecule
Upfront Cash : $150.0 million
April 11, 2024
Lead Product(s) : Luxdegalutamide,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,160.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.
Brand Name : ARV-766
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 08, 2023
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?